Your browser doesn't support javascript.
A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.
Justice, Jamie N; Gubbi, Sriram; Kulkarni, Ameya S; Bartley, Jenna M; Kuchel, George A; Barzilai, Nir.
  • Justice JN; Sticht Center for Healthy Aging and Alzheimer's Prevention, Internal Medicine - Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA. jnjustic@wakehealth.edu.
  • Gubbi S; Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Kulkarni AS; Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
  • Bartley JM; Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
  • Kuchel GA; Center on Aging, University of Connecticut School of Medicine, Farmington, CT, 06030, USA.
  • Barzilai N; Department of Immunology, University of Connecticut School of Medicine, Farmington, CT, 06030, USA.
Geroscience ; 43(3): 1093-1112, 2021 06.
Artículo en Inglés | MEDLINE | ID: covidwho-1499503
ABSTRACT
We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality occur disproportionately in older adults. Geroscience interventions that target biological aging could decrease risk across multiple age-related diseases and improve outcomes in response to infectious disease. This offers hope for a new host-directed therapeutic approach that could (i) improve outcomes following exposure or shorten treatment regimens; (ii) reduce the chronic pathology associated with the infectious disease and subsequent comorbidity, frailty, and disability; and (iii) promote development of immunological memory that protects against relapse or improves response to vaccination. We review the possibility of this approach by examining available evidence in metformin a generic drug with a proven safety record that will be used in a large-scale multicenter clinical trial. Though rigorous translational research and clinical trials are needed to test this empirically, metformin may improve host immune defenses and confer protection against long-term health consequences of infectious disease, age-related chronic diseases, and geriatric syndromes.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Enfermedades Transmisibles / COVID-19 / Metformina Tipo de estudio: Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Covid persistente / Vacunas Límite: Anciano / Humanos Idioma: Inglés Revista: Geroscience Año: 2021 Tipo del documento: Artículo País de afiliación: S11357-020-00261-6

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Enfermedades Transmisibles / COVID-19 / Metformina Tipo de estudio: Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Covid persistente / Vacunas Límite: Anciano / Humanos Idioma: Inglés Revista: Geroscience Año: 2021 Tipo del documento: Artículo País de afiliación: S11357-020-00261-6